Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Published on Oct 1, 2021in OncoTargets and Therapy4.147
· DOI :10.2147/OTT.S317570
Muhammad Khawar Sana2
Estimated H-index: 2
(John H. Stroger, Jr. Hospital of Cook County)
Sources
Abstract
References42
Newest
#1Shaji Kumar (Mayo Clinic)H-Index: 128
#2Natalie S. Callander (UW: University of Wisconsin-Madison)H-Index: 51
Last. Rashmi Kumar (National Comprehensive Cancer Network)H-Index: 18
view all 29 authors...
Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
Source
#1Peter M. VoorheesH-Index: 36
#2Jonathan L. Kaufman (Emory University)H-Index: 41
Last. Paul G. Richardson (Harvard University)H-Index: 208
view all 29 authors...
Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCT-eligible NDMM patients. Patients (N=207) were randomized 1:1 to receive RVd +/-D induction (4 cycles), ASCT, RVd +/-D consolidation (2 cycles), and lenalidomide +/-D maintenance (26 cycles). At the primary endpoint analys...
Source
#1Shaji Kumar (Mayo Clinic)H-Index: 128
#2Susanna Jacobus (Harvard University)H-Index: 27
Last. Benjamin M. Parsons (Gundersen Health System)H-Index: 9
view all 20 authors...
LBA3Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in...
Source
#1Somedeb Ball (TTUHSC: Texas Tech University Health Sciences Center)H-Index: 9
#2Tapas Ranjan Behera (Cleveland Clinic)H-Index: 2
Last. Rajshekhar Chakraborty (Cleveland Clinic)H-Index: 18
view all 4 authors...
The incidence and relative risk of kidney toxicity with carfilzomib in multiple myeloma (MM) has been incompletely characterized. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing carfilzomib-based with non-carfilzomib-based regimens in MM to investigate the risk of kidney toxicity. Point estimates were pooled in the form of risk ratios (RR) with 95% confidence intervals (CI) using the random-effects model. We identified four RCTs with 2954 patie...
Source
#1Philippe MoreauH-Index: 122
#2Keith Stewart (Mayo Clinic)H-Index: 14
Last. Maria-Victoria MateosH-Index: 74
view all 16 authors...
Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m(2) (Kd56 BIW) or once weekly at 70 mg/m(2) (Kd70 QW). Post hoc cross-trial comparisons were performed to compare efficacy and safety profiles of Kd70 QW vs Kd56 BIW dosing schedules using data from three trials of patients with RRMM: A.R.R.O.W., CHAMPION-1, and ENDEAVOR. To select for comparable patient populations, si...
Source
#8Veronika Bachanova (UMN: University of Minnesota)H-Index: 5
Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in consolidation and maintenance therapy for MM is less clear. We performed a meta-analysis to evaluate the impact of bortezomib-based consolidation and maintenance therapy on survival outcomes and adverse events. PubMed, Web of Science, Embase databases, and major conference proceedings were searched for randomized controlled trials (RCTs) of bortezomib-based reg...
Source
#1Maria Gavriatopoulou (UoA: National and Kapodistrian University of Athens)H-Index: 34
#2Evangelos Terpos (UoA: National and Kapodistrian University of Athens)H-Index: 87
Last. Meletios A. Dimopoulos (UoA: National and Kapodistrian University of Athens)H-Index: 147
view all 14 authors...
Source
#1Luciano J. Costa (UAB: University of Alabama at Birmingham)H-Index: 42
#2Saurabh Chhabra (MUSC: Medical University of South Carolina)H-Index: 21
Last. Natalie S. Callander (UW: University of Wisconsin-Madison)H-Index: 51
view all 15 authors...
Source
#1Ola Landgren (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 94
#2Malin Hultcrantz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
Last. Neha Korde (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
view all 36 authors...
Source
#1Kwee Yong (UCL: University College London)H-Index: 31
#2Rakesh Popat (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 20
Last. Roger G. Owen (Leeds Teaching Hospitals NHS Trust)H-Index: 28
view all 22 authors...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.